Semaglutide 7.2mg (Wegovy HD), FDA approved in April 2026, is Novo Nordisk's strategic answer to Tirzepatide (Zepbound)'s efficacy — delivering 20.7% mean weight loss at 72 weeks, nearly matching the 20.9% of tirzepatide and well above standard Wegovy's 14.9% ceiling. By tripling the dose of the same semaglutide molecule proven in the SELECT trial, it retains the cardiovascular protection profile (20% MACE reduction at 2.4mg) while closing the efficacy gap to within 0.2 percentage points. Administered once-weekly via a modified high-dose pen with gradual titration. Notably, introductory pricing through August 2026 is $149 monthly self-pay — matching Orforglipron (Foundayo)'s oral pill price and making it the highest-efficacy injectable at that price. Post-August 2026 pricing may change. GI side effects align with known semaglutide tolerability. Ideal for patients on standard Wegovy who plateaued and want to step up within the same molecule.
Comments on "Semaglutide 7.2mg (Wegovy HD)"
Create a free account or sign in to join the discussion.
Sign in to join the conversation